Company Encyclopedia
View More
name
Whitehawk Therapeutics
WHWK.US
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc.
1.912 T
WHWK.USMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking274/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-13.82%E
    • Profit Margin-108.58%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-42.62%E
    • Net Profit YoY74.68%A
    • Total Assets YoY94.89%A
    • Net Assets YoY128.22%A
  • Cash ScoreE
    • Cash Flow Margin-92.10%D
    • OCF YoY-42.62%E
  • Operating ScoreE
    • Turnover0.11E
  • Debt ScoreA
    • Gearing Ratio5.90%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Whitehawk Therapeutics (NASDAQ:WHWK) Now Covered by Jones Trading

    Jones Trading initiated coverage on Whitehawk Therapeutics with a "buy" rating and a $7.00 price target, suggesting a potential 177.78% upside. Other analysts have mixed ratings, with Weiss Ratings issuing a "sell" and Zacks Research upgrading to "hold." The stock has a current price of $2.52 and a market cap of $118.77 million. Institutional investors have recently acquired significant stakes in the company.

    Market Beat·
    US
    WHWK
    -2.73%
    Market Beat·
    US
    WHWK
    -2.73%

    Whitehawk Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Medical Officer Margaret Dugan

    Whitehawk Therapeutics Inc. has filed Form 3, identifying Chief Medical Officer Margaret Dugan as a beneficial owner. This filing was made via EDGAR by the U.S. SEC on December 02, 2025. The information is for informational purposes and not financial advice.

    Reuters·
    US
    WHWK
    -2.73%
    Reuters·
    US
    WHWK
    -2.73%

    Whitehawk Therapeutics Names Margaret Dugan as Chief Medical Officer

    Whitehawk Therapeutics Inc. has appointed Dr. Margaret Dugan as Chief Medical Officer. With over 30 years of experience in oncology drug development, Dr. Dugan will aid in advancing the company's antibody drug conjugate programs toward clinical development. This appointment was announced via PR Newswire on December 01, 2025.

    Reuters·
    US
    WHWK
    -2.73%
    Reuters·
    US
    WHWK
    -2.73%

    Whitehawk Therapeutics CEO to Join Piper Sandler Healthcare Conference Fireside Chat

    Whitehawk Therapeutics Inc.'s CEO, Dave Lennon, will join a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in NYC on December 3, 2025. The event will be webcast live on the company's investor relations site, with a replay available for 30 days. This announcement was originally published by Whitehawk Therapeutics via PR Newswire.

    Reuters·
    US
    WHWK
    -2.73%
    Reuters·
    US
    WHWK
    -2.73%

    Whitehawk Therapeutics unveils ADC pipeline and preclinical data in new corporate presentation

    Whitehawk Therapeutics Inc. has unveiled its ADC pipeline in a corporate presentation, featuring three assets targeting cancer types like non-small cell lung and ovarian. The presentation highlights novel linker-payload technology for enhanced potency and safety. Preclinical data show improved tumor potency and stability. As of September 2025, Whitehawk has $162.6 million in cash, with a runway into 2028. Key investors include Kalehua and Ally Bridge Group.

    Reuters·
    US
    WHWK
    -2.73%
    Reuters·
    US
    WHWK
    -2.73%
    © 2025 Longbridge｜Disclaimer